Trading Update and Notice of Results
Strong performance expected to deliver revenue and adjusted EBITDA growth in the range of 15% to 20%
21 December 2018 – Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, notes the recent movement in its share price and provides an update on trading to date in the six months ending 31 December 2018.
The Group is pleased to announce that it has continued to perform strongly in the first half of the financial year, with good levels of sales activity and customer renewals by dollar value continuing at their historic average of 100%.
In accordance with the Company’s revenue recognition policy, the majority of the revenue resulting from both new and existing contract renewal sales successes will be recognised over future periods, adding to the Group’s long term visibility of revenue under contract.
The Group expects to report increases in both revenue and adjusted EBITDA in the range of 15% to 20% for the six month period ending 31 December 2018, continuing the double digit growth delivered in prior years.
The Group maintains healthy cash reserves and having seen the normal seasonal pattern in collections and outflows, expects operating cash conversion for the 12 months to be over 100%. The Company has access to a further funding facility from the Bank of Scotland of up to $50m and the Group continues to investigate potential opportunities in line with our stated strategy.
With the record sales performance in the previous period, continued sales momentum and high levels of revenue visibility, the Board remains confident in meeting market expectations for the full year ending 30 June 2019.
Notice of Results
The Company will announce results for the six months ended 31 December 2018 on 5 March 2019.
Keith Neilson, CEO of Craneware plc, commented,
“As we close the first half of our financial year, we look to the future with high levels of confidence. The strength of our trading performance to date and double-digit rate of growth demonstrate the ongoing momentum we are experiencing in the business.
“The depth of our solutions and the value they deliver to all strata of customers, including large and complex health systems, allows us to support our customers as they address the challenges resulting from the continued evolution of the US Healthcare market and the Affordable Care Act. We are playing an increasingly strategic role in assisting healthcare providers as they look to improve and sustain their financial performance, whilst mitigating operational and compliance risks.
“Our financial strength and high levels of revenue visibility for future years combine to give management confidence in its ongoing ability to deliver increasing stakeholder value this year and in the future.”
Keith Neilson, CEO / Craig Preston, CFO
|+44 (0)131 550 3100|
|Peel Hunt (NOMAD and Joint Broker)|
Dan Webster / George Sellar / Guy Pengelley
|+44 (0)20 7418 8900|
|Investec Bank (Joint Broker)|
Patrick Robb/ Sebastian Lawrence / Henry Reast
|+44 (0)20 7597 5970|
|Alma (Financial PR)|
Caroline Forde/ Robyn Fisher / Josh Royston
|+44 (0)203 405 0212|
Craneware enables healthcare providers to improve margins and enhance patient outcomes so they can continue to provide quality outcomes for all.
Craneware is the leader in automated Value Cycle solutions that help US Healthcare provider organisations discover, convert and optimise assets to achieve best clinical outcomes and financial performance. Founded in 1999, Craneware is headquartered in Edinburgh, Scotland with offices in Atlanta and Pittsburgh employing over 320 staff. Craneware’s market-driven, SaaS solutions normalise disparate data sets, bringing in up-to-date regulatory and financial compliance data to deliver value at the points where clinical and operational data transform into financial transactions, creating actionable insights that enable informed tactical and strategic decisions. To learn more, visit craneware.com and thevaluecycle.com.